Ledipasvir D8
| Product Name | Ledipasvir D8 |
|---|---|
| Alternate Names | Ledipasvir Stable Isotopes, Stable Isotopes of Ledipasvir |
| CAT No. | CS-O-13774 |
| CAS No. | 1256388-51-8(Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 897.05 g/mol |
| Mol. For. | C49H46D8F2N8O6 |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Ledipasvir |
| Purity | 95% |
| Therapeutic | Antiretroviral / Anti-HIV |
| Smileys | O=C(N1CC2(CC2)C[C@H]1C3=NC=C(C4=CC=C(C5=CC=C(C6=CC=C7C(NC([C@H]([C@@H]8C[C@H]9CC8)N9C(C(C(C)C)NC(OC)=O)=O)=N7)=C6)C=C%105)C(C%10(F)F)=C4)N3)C(C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])([2H])NC(OC)=O |
| Canonical Smiles | CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC |
| InchIKey | VRTWBAAJJOHBQU-KMWAZVGDSA-N |
| Inchl | InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1 |
| IUPAC | methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Ledipasvir D8 is a deuterated form of Ledipasvir, a potent inhibitor of the NS5A protein of the hepatitis C virus. It is a highly effective drug that is used in combination with other antiviral agents to treat chronic hepatitis C virus infections. Ledipasvir D8 is commonly used in the form of a tablet, and it is taken orally once a day.
The chemical structure of Ledipasvir D8 contains eight deuterium atoms, which are stable isotopes of hydrogen. This makes Ledipasvir D8 more stable and less likely to undergo metabolic breakdown, resulting in a longer half-life compared to Ledipasvir. It is also less likely to be affected by drug-drug interactions, making it a more reliable drug for the treatment of hepatitis C.
Ledipasvir D8 works by inhibiting the NS5A protein, which is essential for the replication of the hepatitis C virus. This prevents the virus from multiplying and spreading in the body, leading to the eventual clearance of the virus.
In conclusion, Ledipasvir D8 is a highly effective antiviral drug used in the treatment of chronic hepatitis C virus infections. Its stability and resistance to drug-drug interactions make it a reliable drug for the successful treatment of this disease.
Get an Instant Quote
Related Compounds
Ledipasvir D6 | Ledipasvir 13C2 D6 | Ledipasvir D16 |